SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2016 / Cilt: 25 - Sayı: 1

A Case of Thyrotoxic Periodic Paralysis: A Rare Cause of Hypokalemia and Importance of Beta Blockers

Tirotoksik Periyodik Paralizi Olgusu: Hipokaleminin Nadir Bir Nedeni ve Beta Blokerlerin Önemi

Ahmet KIYKIM
Cemal KURT
Simge BARDAK
Kenan TURGUTALP
Mehmet Nuri TURAN
Pages
125–127
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report, we describe a TPP patient who developed acute tetraplegia in hours despite the potassium replacement therapy and we discuss the role of beta blockers in the treatment of TPP

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thyrotoxic periodic paralysis (TPP) is a complication of hyperthyroidism that is characterized by increased Na+/K+-ATPase activity.
📊
Key Findings & Data:It can present with weakness and paralysis due to massive intracellular shift of potassium.
💡
Conclusion & Impact:In this case report, we describe a TPP patient who developed acute tetraplegia in hours despite the potassium replacement therapy and we discuss the role of beta blockers in the treatment of TPP
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Thyrotoxic periodic paralysis (TPP) is a complication of hyperthyroidism that is characterized by increased Na+/K+-ATPase activity. It can present with weakness and paralysis due to massive intracellular shift of potassium. Although potassium replacement is given emergently for TPP treatment, it is also important to suppress hyperadrenergic activity as it is responsible for the pathophysiology of the disease. Use of beta blockers is a safe and effective therapeutic option in order to suppress hyperadrenergic activity during an attack. In this case report, we describe a TPP patient who developed acute tetraplegia in hours despite the potassium replacement therapy and we discuss the role of beta blockers in the treatment of TPP

Özet

Tirotoksik periyodik paralizi (TPP), artmış Na+/K+ ATPaz aktivitesi ile karakterize bir hipertiroidi komplikasyonudur. Yüksek miktarda potasyumun hücre içerisine kaymasına bağlı olarak halsizlik ve paralizi ile prezente olabilir. TPP tedavisinde acil potasyum replasmanı verilmekle beraber hastalığın fizyopatolojisinden sorumlu olan aşırı adrenarjik aktivitenin baskılanması da önemlidir. Atak sırasında hiperadrenerjik aktiviteyi baskılamak amacıyla beta bloker kullanımı güvenilir ve etkin bir tedavi seçeneğidir. Bu olgu raporunda potasyum replasmanına rağmen saatler içerisinde akut tetrapleji gelişen bir TPP olgusunu sunduk ve beta blokerlerin TPP tedavisindeki rolünü tartıştık

🔖

Cite This Article

KIYKIM, A., KURT, C., BARDAK, S., TURGUTALP, K., TURAN, M. N. (2022). A Case of Thyrotoxic Periodic Paralysis: A Rare Cause of Hypokalemia and Importance of Beta Blockers. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 25 - Sayı: 1, 125–127. https://ajindex.com/articles/636169

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R: In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ 1991;303:1096-1099 Kung AWC: Clinical review: Thyrotoxic periodic paralysis: A diagnostic challenge. J Clin Endocrinol Metab 2006;91:2490-2495
  2. Lin SH, Huang CL: Mechanism of thyrotoxic periodic paralysis. J Am Soc Nephrol 2012;23:985-988
  3. Manoukian MA, Foote JA, Crapo LM: Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med 1999;159:601-606 Lin SH: Thyrotoxic periodic paralysis. Mayo Clin Proc 2005;80:99- 105 Ober KP: Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore) 1992;71:109-120 Goh SH: Thyrotoxic periodic paralysis: Reports of seven patients presenting with weakness in an Asian emergency department. Emerg Med J 2002;19:78-79
  4. Barahona MJ, Vinagre I, Sojo L, Cubero JM, Pérez A: Thyrotoxic periodic paralysis: A case report and literature review. Clinical Medicine & Research 2009;7:96-98
  5. Floege J, Johnson RJ, Feehally J: Comphrensive Clinical Nephrology (4th ed). Philadelphia, PA: Elsevier Saunders, 2010;118-129
  6. Levey GS, Klein I: Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med 1990;88:642-646
  7. Brown MJ, Brown DC, Murphy MB: Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 1983;309:1414-1419
  8. Ginsberg AM, Clutter WE, Shah SD, Cryer PE: Triiodothyronine-induced thyrotoxicosis increases mononuclear leukocyte/3-adrenergic receptor density in man. J Clin Invest 1981;67:1785-1791.
  9. Ryan DP, Magnus R, Silva DD, Soong TW, Fontaine B, Donaldson MR, Kung AWC, Jongjaroenprasert W, Liang MC, Khoo DHC, Cheah JS, Ho SC, Bernstein HS, Macie RMB, Brown Jr RH, Ptá?cek LJ: Mutations in potassium channel Kir 2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010;140:88-98
  10. Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R: Hyperinsulinaemia and Na+, K(+)-ATPase activity in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf) 1994; 41:213-216
  11. Lu KC, Hsu YJ, Chiu JS, Hsu YD, Lin SH: Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med 2004;22:544-547
  12. Barahona MJ, Vinagre I, Sojo L, Cubero JM, Pérez A: Thyrotoxic periodic paralysis: A case report and literature review. Clin Med Res 2009;7:96-98
  13. Birkhahn RH, Gaeta TJ, Melniker L: Thyrotoxic periodic